文献速递中医内科中药与中成药合理使用

灯盏细辛注射液治疗急性缺血性卒中的系统评价与Meta分析

Chinese herbal medicine Dengzhan Xixin injection for acute ischemic stroke: A systematic review and meta-analysis of randomised controlled trials.
PubMed 文献 · Complement Ther Med · 2017-08-11

该系统评价纳入25项随机对照试验共2498例急性缺血性卒中患者,评估灯盏细辛注射液联合常规治疗的效果与安全性。结果显示联合治疗可能改善神经功能缺损评分和日常生活能力,降低治疗失败率,但证据质量低,对死亡无显著获益,需大样本严谨试验进一步验证。

要点

  • 灯盏细辛注射液联合常规治疗可能改善急性缺血性卒中患者神经功能缺损评分。
  • 联合治疗可能提高Barthel指数评分并降低治疗失败率,但对死亡无显著获益。
  • 纳入研究多数存在高偏倚风险,证据质量低,需大样本严谨试验验证。

核心结论

  • 低质量证据提示灯盏细辛注射液可能改善急性缺血性卒中患者的神经功能。
  • 该潜在获益需在大样本、严谨设计的试验中进一步研究。

研究设计与样本

  • 系统评价与Meta分析,方案注册号CRD42016038413。
  • 检索6个电子数据库至2016年3月,纳入25项随机对照试验共2498例患者。
  • 所有试验两组均采用常规治疗,多数研究存在高偏倚风险。

主要发现

  • 联合灯盏细辛注射液与常规治疗相比,治疗期内(14-35天)死亡风险无显著获益(RR 0.27,95%CI 0.05-1.63)。
  • 联合治疗组Barthel指数评分更高(MD 10.20,95%CI 8.16-12.25)。
  • 联合治疗组神经功能缺损评分更低(NFDS:MD -3.99,95%CI -5.68至-2.30;NIHSS:MD -1.67,95%CI -2.59至-0.76)。
  • 联合治疗组治疗失败率更低(RR 0.40,95%CI 0.31-0.52)。
  • 13项试验(52%)报告了不良事件,但未报告严重不良事件。

关键数值与推荐

  • 死亡:RR 0.27,95%CI 0.05-1.63,治疗期14-35天。
  • Barthel指数:MD 10.20,95%CI 8.16-12.25。
  • 神经功能缺损评分(NFDS):MD -3.99,95%CI -5.68至-2.30。
  • 神经功能缺损评分(NIHSS):MD -1.67,95%CI -2.59至-0.76。
  • 治疗失败:RR 0.40,95%CI 0.31-0.52。

临床怎么用

  • 在常规治疗基础上,灯盏细辛注射液可能作为改善急性缺血性卒中神经功能的辅助选择。
  • 临床决策需结合低质量证据背景,充分评估获益与不确定性。
  • 使用中应关注不良事件监测,尽管未报告严重不良事件。

局限性

  • 纳入研究多数存在高偏倚风险,整体证据质量低。
  • 仅52%的试验报告了不良事件结局。
  • 治疗期死亡事件少,死亡结局的置信区间宽。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness and safety of Chinese herbal medicine Dengzhan Xixin (Erigeron breviscapus) injection for acute ischemic stroke. DESIGN: Systematic review and meta-analysis (CRD42016038413, http://www.crd.york.ac.uk/PROSPERO). METHODS: Six electronic databases were searched from inception to March 2016 for randomised controlled trials (RCTs) of Dengzhan Xixin (DZXX) injection for acute ischemic stroke. The methodological quality of RCTs was assessed by the Cochrane risk of bias tool. DATA SYNTHESIS: was performed using RevMan 5.3 and was presented with mean difference (MD) or relative risk (RR) and their 95% confidence interval (CI). A summary of finding table was generated by GRADEpro (version 3.6). RESULTS: Twenty-five RCTs with 2498 participants were included and all trials adopted conventional therapy (CT) in both arms. Most of the studies had high risk of bias. The addition of DZXX to CT showed no significant benefit on death (RR 0.27, 95% CI 0.05-1.63) within the treatment period (14-35 d), but showed higher Barthel index score (MD 10.20, 95% CI 8.16-12.25), lower neurological function deficit score (MD -3.99, 95% CI -5.68 to -2.30, by NFDS; MD -1.67, 95% CI -2.59 to -0.76, by NIHSS), and lower treatment failure (RR 0.40, 95% CI 0.31-0.52). Thirteen trials (52%) reported the outcome of adverse events, but no serious adverse events were reported. CONCLUSION: Low quality evidence implied that DZXX injection appeared to improve neurological function in patients with acute ischemic stroke. However, this potential benefit should be further studied in large, rigorous trials.

来源:Complement Ther Med,查看原文。版权归原作者所有。

引用

  1. Li JG, Wang LQ, Yang XY, et al. Chinese herbal medicine Dengzhan Xixin injection for acute ischemic stroke: A systematic review and meta-analysis of randomised controlled trials. Complement Ther Med. 2017. PMID: 28917378. doi:10.1016/j.ctim.2017.08.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。